Alcobra Ltd (ADHD.O)

ADHD.O on Consolidated Issue listed on NASDAQ Global Market

6.17USD
30 Jan 2015
Change (% chg)

$-0.22 (-3.44%)
Prev Close
$6.39
Open
$6.31
Day's High
$6.39
Day's Low
$5.84
Volume
238,619
Avg. Vol
307,906
52-wk High
$25.44
52-wk Low
$3.12

ADHD.O

Chart for ADHD.O

About

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and... (more)

Overall

Beta: --
Market Cap(Mil.): $130.67
Shares Outstanding(Mil.): 21.18
Dividend: --
Yield (%): --

Financials

  ADHD.O Industry Sector
P/E (TTM): -- 188.86 38.54
EPS (TTM): -2.35 -- --
ROI: -142.69 -1.23 18.06
ROE: -142.69 -3.07 18.83
Search Stocks

Alcobra ADHD drug meets goals, after data excluded; stock tanks

- Alcobra Ltd lost more than half its market value after it said its drug to treat adult attention deficit disorder met the main goals of a late-stage trial - but only after excluding data from patients who reacted positively to a placebo.

06 Oct 2014

UPDATE 2-Alcobra ADHD drug meets goals, after data excluded; stock tanks

(Adds conference call details; CEO , analyst comments; updates shares)

06 Oct 2014

US STOCKS-Small biotech stocks plummet in premarket

NEW YORK, Oct 6 - Sunesis Pharmaceuticals and Alcobra Ltd were both sharply lower in premarket trading on Monday, with both names tumbling on heavy volume after reporting the results of late-stage drug trials.

06 Oct 2014

Alcobra's ADHD drug meets goals in late-stage study

Oct 6 - Alcobra Ltd said its drug to treat attention deficit disorder met the main goals of a late-stage trial, reducing the symptoms of the condition better than a sugar pill.

06 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$49.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks